Back to search
Locally Advanced or Metastatic EGFR T790M+ NSCLC
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Locally Advanced or Metastatic EGFR T790M+ NSCLC trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Locally Advanced or Metastatic EGFR T790M+ NSCLC trials you may qualify forThis study is conducted to evaluate the efficacy and safety of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring T790M…
The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor（EGFR-TKI） osimertinib has obvious curative effect for EGFR sensitive mutation an…
The primary goal is to evaluate the efficacy of osimertinib (AZD9291), in terms of the objective response rate in patients with advanced non-squamous NSCLC with…